Connection
James Burton to Protease Inhibitors
This is a "connection" page, showing publications James Burton has written about Protease Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.896 |
|
|
|
-
Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014 Sep; 61(3):508-14.
Score: 0.439
-
Burton JR, Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis. 2009 Aug; 13(3):453-65.
Score: 0.316
-
MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
Score: 0.141